UY38485A - Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación - Google Patents
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparaciónInfo
- Publication number
- UY38485A UY38485A UY0001038485A UY38485A UY38485A UY 38485 A UY38485 A UY 38485A UY 0001038485 A UY0001038485 A UY 0001038485A UY 38485 A UY38485 A UY 38485A UY 38485 A UY38485 A UY 38485A
- Authority
- UY
- Uruguay
- Prior art keywords
- pcsk9
- treatment
- preparation
- inhibitors
- proprotein convertase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
Abstract
La invención se refiere a inhibidores de PCSK9 de utilidad en el tratamiento del metabolismo de los lípidos del colesterol y otras enfermedades en las que PCSK9 interviene, que tienen la fórmula (I): o una sal, hidrato, solvato, profármaco, estereoisómero, N-óxido o tautómero farmacéuticamente aceptable de los mismos, en donde R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, y X3 están descriptos en la presente. Adicionalmente, se describen métodos de tratamiento, su uso y su preparación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862772030P | 2018-11-27 | 2018-11-27 | |
US201962924828P | 2019-10-23 | 2019-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38485A true UY38485A (es) | 2020-06-30 |
Family
ID=68808460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038485A UY38485A (es) | 2018-11-27 | 2019-11-22 | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
Country Status (24)
Country | Link |
---|---|
US (2) | US11026993B2 (es) |
EP (1) | EP3887365A1 (es) |
JP (1) | JP2022507957A (es) |
KR (1) | KR20210096154A (es) |
CN (1) | CN113166114A (es) |
AU (1) | AU2019387294B2 (es) |
BR (1) | BR112021009857A2 (es) |
CA (1) | CA3115960A1 (es) |
CL (1) | CL2021001365A1 (es) |
CO (1) | CO2021006895A2 (es) |
CR (1) | CR20210267A (es) |
CU (1) | CU20210043A7 (es) |
DO (1) | DOP2021000100A (es) |
EC (1) | ECSP21036194A (es) |
IL (1) | IL283374A (es) |
JO (1) | JOP20210120A1 (es) |
MA (1) | MA54284A (es) |
MX (1) | MX2021006069A (es) |
PE (1) | PE20211658A1 (es) |
PH (1) | PH12021551049A1 (es) |
SG (1) | SG11202103807WA (es) |
TW (1) | TW202038990A (es) |
UY (1) | UY38485A (es) |
WO (1) | WO2020110009A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11882610B2 (en) * | 2020-08-13 | 2024-01-23 | Qualcomm Incorporated | Establishing connections using multiple subscriber identity modules via a single communication link |
CN114163343A (zh) * | 2021-12-10 | 2022-03-11 | 许昌学院 | 含氟氨基酸及衍生物含氟多肽的制备方法以及应用 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | 糖尿病治療に有用なglp―1アナログ |
US5155100A (en) | 1991-05-01 | 1992-10-13 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipeptide derivatives |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
IT1291776B1 (it) | 1997-02-07 | 1999-01-21 | Menarini Ricerche Spa | Composti monociclici a quattro residui bifunzionali, aventi azione nk-2 antagonista |
IT1304888B1 (it) | 1998-08-05 | 2001-04-05 | Menarini Ricerche Spa | Composti monociclici ad azione nk-2 antagonista e formulazioni che licontengono |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
IT1307809B1 (it) | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono. |
MXPA02010091A (es) | 2000-04-12 | 2003-02-12 | Novartis Ag | Novedoso uso medico de inhibidores de sintasa de aldosterona solos o en combinacion con antagonistas del receptor at-1. |
EP1297826A1 (en) | 2001-09-27 | 2003-04-02 | Menarini Ricerche S.p.A. | Nasal pharmaceutical compositions containing a NK-2 antagonist |
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
AU2003232941A1 (en) | 2002-06-07 | 2003-12-22 | Glaxo Group Limited | N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them |
ES2270143T3 (es) | 2002-08-07 | 2007-04-01 | Novartis Ag | Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona. |
ATE398124T1 (de) | 2002-11-18 | 2008-07-15 | Novartis Pharma Gmbh | Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron |
CA2525764C (en) | 2003-05-20 | 2012-07-17 | Novartis Ag | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
EP2261225A1 (en) | 2004-05-28 | 2010-12-15 | Novartis AG | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
DE602005025110D1 (de) | 2004-05-28 | 2011-01-13 | Novartis Ag | Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren |
CA2568159A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors |
TW200611897A (en) | 2004-07-09 | 2006-04-16 | Speedel Experimenta Ag | Organic compounds |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
SI2402317T1 (sl) | 2006-03-31 | 2013-10-30 | Novartis Ag | DGAT inhibitor |
CN101415803B (zh) | 2006-04-04 | 2012-10-24 | 大阳日酸株式会社 | 甲烷分离方法、甲烷分离装置以及甲烷利用*** |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
JP2010501573A (ja) | 2006-08-25 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | アルドステロン合成酵素および/または11−β−ヒドロキシラーゼおよび/またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体 |
KR20090094374A (ko) | 2006-12-18 | 2009-09-04 | 노파르티스 아게 | 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도 |
MX2009006630A (es) | 2006-12-18 | 2009-06-30 | Novartis Ag | Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. |
EA200900811A1 (ru) | 2006-12-18 | 2009-12-30 | Новартис Аг | Имидазолы в качестве ингибиторов альдостеронсинтазы |
WO2008119744A1 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | Heterocyclic spiro-compounds |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
JP2010538071A (ja) | 2007-09-07 | 2010-12-09 | セラヴァンス, インコーポレーテッド | 二重作用性降圧剤 |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
EP2297113A1 (en) | 2008-04-29 | 2011-03-23 | Theravance, Inc. | Dual-acting antihypertensive agents |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
JP5773495B2 (ja) | 2008-10-23 | 2015-09-02 | ステバ バイオテック、エス.エイ. | Rgd含有ペプチド模倣体及びその使用 |
MA33358B1 (fr) | 2009-05-15 | 2012-06-01 | Novartis Ag | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase |
KR101442897B1 (ko) | 2009-05-28 | 2014-09-23 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체 |
AR076706A1 (es) | 2009-05-28 | 2011-06-29 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de neprilisina |
DK2483266T3 (en) * | 2009-10-01 | 2015-06-01 | Cadila Healthcare Ltd | Compounds for the treatment of dyslipidemia and related diseases |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
WO2011063366A1 (en) | 2009-11-23 | 2011-05-26 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
CA2817368C (en) | 2010-12-15 | 2019-12-31 | Theravance, Inc. | Neprilysin inhibitors |
JP5959065B2 (ja) | 2011-02-17 | 2016-08-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
CA2835216A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
CN103748070B (zh) | 2011-05-31 | 2015-06-24 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
WO2013184934A1 (en) | 2012-06-08 | 2013-12-12 | Theravance, Inc. | Neprilysin inhibitors |
DE102012014480A1 (de) | 2012-07-21 | 2014-01-23 | Daimler Ag | Aufbau eines Innendekors |
SI2882716T1 (sl) | 2012-08-08 | 2017-04-26 | Theravance Biopharma R&D Ip, Llc | Zaviralci neprilizina |
US20150218212A1 (en) | 2012-08-21 | 2015-08-06 | Fluorinov Pharma Inc. | Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors |
MX367525B (es) | 2013-02-14 | 2019-08-26 | Novartis Ag | Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep). |
US8901169B2 (en) | 2013-03-05 | 2014-12-02 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
CA2904662A1 (en) | 2013-03-15 | 2014-09-25 | Shifa Biomedical Corporation | Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases |
EP3099668B1 (en) | 2014-01-30 | 2022-05-04 | Theravance Biopharma R&D IP, LLC | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors |
ES2718239T3 (es) | 2014-01-30 | 2019-06-28 | Theravance Biopharma R&D Ip Llc | Inhibidores de neprilisina |
TW201823222A (zh) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | 化合物、醫藥組成物及其用途 |
-
2019
- 2019-11-22 UY UY0001038485A patent/UY38485A/es unknown
- 2019-11-25 TW TW108142721A patent/TW202038990A/zh unknown
- 2019-11-26 CU CU2021000043A patent/CU20210043A7/es unknown
- 2019-11-26 EP EP19816905.4A patent/EP3887365A1/en active Pending
- 2019-11-26 JP JP2021529266A patent/JP2022507957A/ja active Pending
- 2019-11-26 AU AU2019387294A patent/AU2019387294B2/en active Active
- 2019-11-26 BR BR112021009857-7A patent/BR112021009857A2/pt not_active Application Discontinuation
- 2019-11-26 CN CN201980076002.XA patent/CN113166114A/zh active Pending
- 2019-11-26 JO JOP/2021/0120A patent/JOP20210120A1/ar unknown
- 2019-11-26 WO PCT/IB2019/060201 patent/WO2020110009A1/en unknown
- 2019-11-26 SG SG11202103807WA patent/SG11202103807WA/en unknown
- 2019-11-26 MX MX2021006069A patent/MX2021006069A/es unknown
- 2019-11-26 MA MA054284A patent/MA54284A/fr unknown
- 2019-11-26 PE PE2021000749A patent/PE20211658A1/es unknown
- 2019-11-26 CR CR20210267A patent/CR20210267A/es unknown
- 2019-11-26 CA CA3115960A patent/CA3115960A1/en active Pending
- 2019-11-26 US US16/695,843 patent/US11026993B2/en active Active
- 2019-11-26 KR KR1020217019281A patent/KR20210096154A/ko unknown
-
2021
- 2021-03-12 US US17/200,471 patent/US11813306B2/en active Active
- 2021-05-06 PH PH12021551049A patent/PH12021551049A1/en unknown
- 2021-05-21 EC ECSENADI202136194A patent/ECSP21036194A/es unknown
- 2021-05-23 IL IL283374A patent/IL283374A/en unknown
- 2021-05-24 DO DO2021000100A patent/DOP2021000100A/es unknown
- 2021-05-25 CO CONC2021/0006895A patent/CO2021006895A2/es unknown
- 2021-05-25 CL CL2021001365A patent/CL2021001365A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210096154A (ko) | 2021-08-04 |
AU2019387294A1 (en) | 2021-05-13 |
WO2020110009A1 (en) | 2020-06-04 |
BR112021009857A2 (pt) | 2021-08-17 |
AU2019387294B2 (en) | 2022-09-08 |
IL283374A (en) | 2021-07-29 |
US20210252103A1 (en) | 2021-08-19 |
SG11202103807WA (en) | 2021-06-29 |
JP2022507957A (ja) | 2022-01-18 |
PE20211658A1 (es) | 2021-08-24 |
MA54284A (fr) | 2022-03-02 |
CA3115960A1 (en) | 2020-06-04 |
CL2021001365A1 (es) | 2022-01-14 |
MX2021006069A (es) | 2021-07-06 |
US20200164024A1 (en) | 2020-05-28 |
US11026993B2 (en) | 2021-06-08 |
DOP2021000100A (es) | 2021-06-30 |
CN113166114A (zh) | 2021-07-23 |
CU20210043A7 (es) | 2022-01-13 |
CO2021006895A2 (es) | 2021-06-10 |
EP3887365A1 (en) | 2021-10-06 |
JOP20210120A1 (ar) | 2023-01-30 |
US11813306B2 (en) | 2023-11-14 |
PH12021551049A1 (en) | 2021-12-06 |
TW202038990A (zh) | 2020-11-01 |
CR20210267A (es) | 2021-08-16 |
ECSP21036194A (es) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
ECSP19043710A (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
AR105808A1 (es) | Compuestos de amida para el tratamiento de trastornos médicos | |
CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
CR20110608A (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
DOP2012000312A (es) | Triazolopiridinas sustituidas | |
CY1123532T1 (el) | Αναστολεις του gingipain λυσινης | |
CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
UY38485A (es) | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
EA201490495A1 (ru) | Новые легкоразрушающиеся ингибиторы rock | |
AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
EA201692045A1 (ru) | Производное фенантролинфосфоновой кислоты и способ его получения и применения |